SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Thiazolidinediones (TDZs), e.g., pioglitazone, rosiglitazone [148,149], glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), e.g., lixisenatide, liraglutide, dulaglutide, semaglutide [148,150,151] and sodium-glucose transport protein 2 (SGLT2) inhibitors, e.g., empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin [152,153] are effective in controlling the blood glucose level, reducing risk of cardiovascular diseases, and giving the positive clinical outcome of diverse liver disorders including NAFLD [154-156].